INVESTORS

Press Releases


Press Releases

June 27, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224...
June 21, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a...
May 31, 2022
New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 DURHAM, N.C. --(BUSINESS WIRE)--May 31, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic...
May 23, 2022
New Senior Executive Brings 25 Years of Human Resources Leadership and Pharma Industry Experience DURHAM, N.C. --(BUSINESS WIRE)--May 23, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene...
Displaying 1 - 10 of 18